Prehabilitation Care for Women With Advanced Ovarian Cancer Receiving Neoadjuvant Chemotherapy

Active, not recruiting

• Conditions: Fallopian Tube Cancer; Ovarian Cancer; Stage III Ovarian Cancer; Stage IV Ovarian Cancer; Primary Peritoneal Carcinoma; Fallopian Tube Carcinoma
• Interventions: Other: Prehabilitation

• Registration Number: NCT04204811
• Lead Sponsor: Memorial Sloan Kettering Cancer Center

Brief Summary

The purpose of this study is evaluate whether a prehabilitation program is feasible and useful for women with advanced ovarian cancer receiving chemotherapy in preparation for debulking surgery.

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study Start: 2019-12-16
• Study First Submitted: 2019-12-17
• Study First Submitted QC: 2019-12-17
• Study First Posted: 2019-12-19
• Status Verified: 2025-01
• Last Update Submitted: 2025-01-02
• Last Update Posted: 2025-01-03
• Primary Completion: 2025-12-16
• Study Completion: 2025-12-16

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: Female
• Target Recruitment: 22

Inclusion Criteria

• Subjects must be diagnosed with Stage III or Stage IV ovarian carcinoma (which includes primary peritoneal carcinoma or fallopian rube carcinoma)
• All subjects must be enrolled within 90 days of diagnosis
• No prior treatment for ovarian carcinoma
• All subjects have agreed to a treatment plan of neoadjuvant chemotherapy and subsequent planned interval debulking surgery with an MSKCC surgeon
• Participants must be initiating treatment at Gynecologic Medical Oncology clinics at MSKCC Manhattan
• Proficiency in English in the determination of the investigators of by patient self-report

Read More

Exclusion Criteria

• Patient under age 18
• Prior treatment for ovarian cancer
• Second opinion visit only
• Immediate surgery plan without neoadjuvant treatment
• No intended surgical plan
• Chemotherapy administration exclusively planned at MSKCC regional site
• Patient unwilling to sign consent

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Participants with Ovarian Cancer	Prehabilitation	Participants are diagnosed with Stage III or Stage IV ovarian carcinoma (which includes primary peritoneal carcinoma or fallopian tube carcinoma)

Primary Outcome Measures

Name	Time	Method
Median completion of participants	Up to 1 year	Study will be considered feasible if the cohort has a median completion of 70% or more

Trial Locations

Locations (1)

Memorial Sloan Kettering Cancer Center; 🇺🇸 New York, New York, United States